SPY468.28+9.49 2.07%
DIA357.74+4.92 1.39%
IXIC15,686.92+461.76 3.03%

JMP Securities Maintains Market Outperform on Taysha Gene Therapies, Lowers Price Target to $38

JMP Securities analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and lowers the price target from $40 to $38.

Benzinga · 11/11/2021 07:04
JMP Securities analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and lowers the price target from $40 to $38.